• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    RedChip CEO Dave Gentry Invited to Join Forbes Business Council

    1/25/23 8:00:00 AM ET
    $AREC
    $BIVI
    $GNS
    $RVPH
    Coal Mining
    Energy
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AREC alert in real time by email

    ORLANDO, FL / ACCESSWIRE / January 25, 2023 / RedChip Companies is pleased to announce its CEO, Dave Gentry, was recently welcomed as a member of the Forbes Business Council.

    The Forbes Business Council committee invited Gentry to join the elite group of business leaders in recognition of his passion for helping entrepreneurs achieve success. The invitation-only community is made up of successful business owners and executives who have been chosen based on their accomplishments and experience.

    As a member, Gentry will be able to leverage the Forbes Business Council's collective resources to help foster growth in the RedChip Companies community. He will also be able to participate in exclusive events, such as invite-only webinars and podcasts, publish expert insights as a contributing writer on the Forbes platform, access a private community of members, and more.

    Gentry commented, "I look forward to sharing insights gained from my decades of experience working with executives in the small-cap markets. I believe this is a great opportunity to enhance my contributions to the entrepreneurial spirit that drives business innovations globally, while also gaining valuable new insights from industry veterans."

    Gentry is the author of Small Stocks, Big Money, a Wiley-published book of interviews with the world's most successful small-cap investors. He has been a consultant to more than 1,000 public companies and assisted dozens of public companies in the up-listing and capital-raising process. In 2012 he founded The RedChip Money Report™, a weekly cable TV financial news show broadcast in 177 million homes. He has appeared on CNBC and Fox Business News and is widely known as a thought leader in the small-cap space.

    Gentry has been a presenter at the New York Society of Security Analysts, Deal Flow Media conferences, and other small-cap conferences, and he has rung the NASDAQ bell on three occasions. In 2011, he was honored by Inc. Magazine as CEO of one of the fastest-growing private companies in America. In 1996, he won the Republican nomination in the 5th District of Florida for the United States House of Representatives. In 1994 he co-founded the First Amendment Coalition, an independent, nonprofit, collegiate-based student organization, and received national and international attention for his work defending free speech on college campuses. Gentry's activism led to his book 100+ Cases of Campus Censorship, published by David Horowitz's Second Thoughts Books. Gentry earned his Master of Education from the University of Florida in 1993.

    RedChip currently represents more than 70 clients, including some of the best emerging growth companies in the small-cap space, such as Genius Group (NYSE:GNS), Reviva Pharmaceuticals (NASDAQ:RVPH), Zomedica (NYSE:ZOM), BioVie (NASDAQ:BIVI), and American Resources Corporation (NASDAQ:AREC).

    About Forbes Business Council

    The Forbes Business Council is an exclusive platform that brings together successful business owners and executives from all over the world. Members are handpicked by the Forbes Business Council committee based on their accomplishments, experience, and commitment to helping entrepreneurs reach their goals.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Contact:

    Matt Sheldon
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    [email protected]

    SOURCE: RedChip



    View source version on accesswire.com:
    https://www.accesswire.com/736680/RedChip-CEO-Dave-Gentry-Invited-to-Join-Forbes-Business-Council

    Get the next $AREC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AREC
    $BIVI
    $GNS
    $RVPH

    CompanyDatePrice TargetRatingAnalyst
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/20/2023$12.00Buy
    ROTH MKM
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    6/8/2023$17.00Speculative Buy
    The Benchmark Company
    Zomedica Corp.
    $ZOM
    1/6/2023$6.00Buy
    Dawson James
    BioVie Inc.
    $BIVI
    7/22/2022$7.00Overweight
    Cantor Fitzgerald
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    1/24/2022$10.00Buy
    HC Wainwright & Co.
    BioVie Inc.
    $BIVI
    11/30/2021$50.00 → $27.00Buy
    B. Riley Securities
    American Resources Corporation
    $AREC
    11/16/2021$4.00 → $3.75Buy
    HC Wainwright & Co.
    American Resources Corporation
    $AREC
    8/18/2021$4.50 → $4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AREC
    $BIVI
    $GNS
    $RVPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

      CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in a Guided Poster Tour session at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025), being held May 7-10, 2025, in New York City. Details for the presentation are as follows: Title: Assessment of Bezisterim (NE3107) in Pati

      5/7/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

      The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

      5/5/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genius Group Announces 2024 Financial Results, 303% NAV Growth

      Increase in Net Asset Value (NAV) to $79.4 million from $19.7 million in 2023. SINGAPORE, April 30, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE:GNS) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group, announced today its financial results for the year ended December 31, 2024. Business Highlights for Fiscal 2024 As a result of the restructured financials due to the failed asset purchase agreement currently the subject of arbitration and the RICO lawsuit filed by the Company, 2024 audited revenue of $7.9 million compared to $23.1 million in 2023.5.8 million students and users compared to 5.5 million in 2023.Reduction in cost of revenue to $5.3 m

      4/30/25 8:15:00 AM ET
      $GNS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary

    $AREC
    $BIVI
    $GNS
    $RVPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Rowe Jeffrey M bought $96,098 worth of shares (1,439,005 units at $0.07) (SEC Form 4)

      4/A - Zomedica Corp. (0001684144) (Issuer)

      3/27/25 9:56:49 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Williams Rodney James bought $6,900 worth of shares (100,000 units at $0.07), increasing direct ownership by 62% to 261,900 units (SEC Form 4)

      4 - Zomedica Corp. (0001684144) (Issuer)

      3/20/25 9:52:31 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Chief Financial Officer Jordan Scott bought $18,600 worth of shares (300,000 units at $0.06) (SEC Form 4)

      4 - Zomedica Corp. (0001684144) (Issuer)

      3/19/25 11:47:14 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    Leadership Updates

    Live Leadership Updates

    See more
    • BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

      The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

      5/5/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Appoints John H. Johnson as Executive Chairman

      Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

      12/20/24 7:00:00 AM ET
      $APLT
      $RVPH
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer

      Seasoned executive brings a broad skill set to Zomedica's leadership team ANN ARBOR, MI / ACCESSWIRE / December 19, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Scott A. Jordan as its Executive Vice President, Finance and Chief Financial Officer, effective January 1, 2025."Scott brings a broad range of skills and experience that will be increasingly important to us as we move forward," said Larry Heaton, Zomedica's Chief Executive Officer. We are excited to welcome him to the Zomedica team and look forward to leveraging his expertis

      12/19/24 6:30:00 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    SEC Filings

    See more
    • SEC Form 6-K filed by Genius Group Limited

      6-K - Genius Group Ltd (0001847806) (Filer)

      5/8/25 8:00:30 AM ET
      $GNS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • SEC Form PRE 14C filed by BioVie Inc.

      PRE 14C - BIOVIE INC. (0001580149) (Filer)

      5/7/25 5:20:08 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Genius Group Limited

      6-K - Genius Group Ltd (0001847806) (Filer)

      5/1/25 9:15:17 AM ET
      $GNS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary

    $AREC
    $BIVI
    $GNS
    $RVPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Genius Group Limited

      SC 13G - Genius Group Ltd (0001847806) (Subject)

      11/14/24 5:32:28 PM ET
      $GNS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Reviva Pharmaceuticals Holdings Inc.

      SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

      11/14/24 5:16:56 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Reviva Pharmaceuticals Holdings Inc.

      SC 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

      11/14/24 4:15:57 PM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    Financials

    Live finance-specific insights

    See more
    • BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

      CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in a Guided Poster Tour session at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025), being held May 7-10, 2025, in New York City. Details for the presentation are as follows: Title: Assessment of Bezisterim (NE3107) in Pati

      5/7/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled

      SUNRISE-PD evaluating the Company's anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson's disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one of very few clinical trials for a Parkinson's disease treatment to incorporate a decentralized approach option to allow for remote participation Patient enrollment has commenced, with recruitment being supported by The Michael J. Fox Foundation, Davis Phinney Foundation and The Parkinson's Foundation Topline data anticipated in Late 2025 or Early 2026 CARSON CITY, Nev., April 16, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company devel

      4/16/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genius Group calls EGM to approve share buyback, cancels rights offering.

      SINGAPORE, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE:GNS) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group, announced today that its Board of Directors (the "Board") has called for an EGM for shareholders to authorize the Board to carry out a share buyback of up to 20% of the issued share capital of the Company, and to approve the creation of a new class of ordinary shares and preferred shares. In light of the Company's current share price below the exercise price of its previously announced rights offering, the Board has also voted to cancel the rights offering at this time. The Company will continue with its plan to increase its B

      2/12/25 8:00:00 AM ET
      $GNS
      Services-Misc. Amusement & Recreation
      Consumer Discretionary

    $AREC
    $BIVI
    $GNS
    $RVPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Rowe Jeffrey M bought $96,098 worth of shares (1,439,005 units at $0.07) (SEC Form 4)

      4/A - Zomedica Corp. (0001684144) (Issuer)

      3/27/25 9:56:49 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Williams Rodney James bought $6,900 worth of shares (100,000 units at $0.07), increasing direct ownership by 62% to 261,900 units (SEC Form 4)

      4 - Zomedica Corp. (0001684144) (Issuer)

      3/20/25 9:52:31 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care
    • Chief Financial Officer Jordan Scott bought $18,600 worth of shares (300,000 units at $0.06) (SEC Form 4)

      4 - Zomedica Corp. (0001684144) (Issuer)

      3/19/25 11:47:14 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Reviva Pharmaceuticals with a new price target

      ROTH MKM initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      9/20/23 7:22:47 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Benchmark Company initiated coverage on Reviva Pharmaceuticals with a new price target

      The Benchmark Company initiated coverage of Reviva Pharmaceuticals with a rating of Speculative Buy and set a new price target of $17.00

      6/8/23 7:41:12 AM ET
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dawson James initiated coverage on Zomedica Pharmaceuticals with a new price target

      Dawson James initiated coverage of Zomedica Pharmaceuticals with a rating of Buy and set a new price target of $6.00

      1/6/23 9:00:39 AM ET
      $ZOM
      Pharmaceuticals and Biotechnology
      Health Care